Low-Dose Aspirin Use Does Not Increase Survival in 2 Independent Population-Based Cohorts of Patients With Esophageal or Gastric Cancer.

BACKGROUND & AIMS Preclinical studies have shown aspirin to have anticancer properties and epidemiologic studies have associated aspirin use with longer survival times of patients with cancer. We studied 2 large cohorts to determine the association between aspirin use and cancer-specific mortality in patients with esophageal or gastric cancer. METHODS We performed a population-based study using cohorts of patients newly diagnosed with esophageal or gastric cancer, identified from cancer registries in England from 1998 through 2012 and the Scottish Cancer Registry from 2009 through 2012. Low-dose aspirin prescriptions were identified from linkages to the United Kingdom Clinical Research Practice Datalink in England and the Prescribing Information System in Scotland. Deaths were identified from linkage to national mortality records, with follow-up until September 2015 in England and January 2015 in Scotland. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific mortality by low-dose aspirin use after adjusting for potential confounders. Meta-analysis was used to pool results across the 2 cohorts. RESULTS The combined English and Scottish cohorts contained 4654 patients with esophageal cancer and 3833 patients with gastric cancer, including 3240 and 2392 cancer-specific deaths, respectively. The proportions surviving 1 year, based on cancer-specific mortality, were similar in aspirin users vs non-users after diagnosis with esophageal cancer (48% vs 50% in England and 49% vs 46% in Scotland, respectively) or gastric cancer (58% vs 57% in England and 59% vs 55% in Scotland, respectively). There was no association between postdiagnosis use of low-dose aspirin and cancer-specific mortality among patients with esophageal cancer (pooled adjusted HR, 0.98; 95% CI, 0.89-1.09) or gastric cancer (pooled adjusted HR, 0.96; 95% CI, 0.85-1.08). Long-term aspirin use was not associated with cancer-specific mortality after diagnosis of esophageal cancer (pooled adjusted HR, 1.03; 95% CI, 0.85-1.25) or gastric cancer (pooled adjusted HR, 1.06; 95% CI, 0.85-1.32). CONCLUSIONS In analyses of 2 large independent cohorts in the United Kingdom, low-dose aspirin usage was not associated with increased survival of patients diagnosed with esophageal or gastric cancer.

[1]  K. Bennett,et al.  Patterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life , 2017, Supportive Care in Cancer.

[2]  H. Putter,et al.  Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study , 2017, British Journal of Cancer.

[3]  D. Cameron,et al.  ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours , 2016, Contemporary clinical trials.

[4]  Simon Tavaré,et al.  Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance , 2016, Nature Genetics.

[5]  A. Neugut,et al.  Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients , 2016, Therapeutic advances in gastroenterology.

[6]  D. Buist,et al.  Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[7]  C. V. D. van de Velde,et al.  The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients , 2016, British Journal of Cancer.

[8]  P. Murchie,et al.  Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer. , 2015, Cancer epidemiology.

[9]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[10]  M. Pollak,et al.  The use of aspirin and the risk of mortality in patients with prostate cancer. , 2015, The Journal of urology.

[11]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[12]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[13]  G. Batist,et al.  Use of statins and the risk of death in patients with prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Weiss,et al.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. , 2013, Journal of the National Cancer Institute.

[15]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[16]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[17]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[18]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[19]  C. Holmes,et al.  The platelet contribution to cancer progression , 2011, Journal of thrombosis and haemostasis : JTH.

[20]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[21]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[22]  R. Perera,et al.  Adaptation and validation of the Charlson Index for Read/OXMIS coded databases , 2010, BMC family practice.

[23]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[24]  I. White,et al.  Imputing missing covariate values for the Cox model , 2009, Statistics in medicine.

[25]  P. Drew,et al.  A Preliminary Study on the Postoperative Survival of Patients Given Aspirin After Resection for Squamous Cell Carcinoma of the Esophagus or Adenocarcinoma of the Cardia , 2009, Annals of Surgical Oncology.

[26]  J. Lewis,et al.  Chronic statin therapy and the risk of colorectal cancer , 2008, Pharmacoepidemiology and drug safety.

[27]  K. Rothman,et al.  Using prescription claims data for drugs available over‐the‐counter (OTC) , 2007, Pharmacoepidemiology and drug safety.

[28]  H. Quan,et al.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. , 2004, Journal of clinical epidemiology.

[29]  A. Chuchalin,et al.  Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. , 2002, Respiratory medicine.

[30]  P. Croft,et al.  Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[31]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[32]  K. Carlsen,et al.  Asthma drug adherence in a long term clinical trial , 2000, Archives of disease in childhood.

[33]  S. Coughlin.  Recall bias in epidemiologic studies. , 1990, Journal of clinical epidemiology.

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[35]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.

[36]  V. Livolsi.  Anti-metastatic effect of aspirin. , 1973, Lancet.

[37]  C. Stewart,et al.  Antimetastatic effects associated with platelet reduction. , 1968, Proceedings of the National Academy of Sciences of the United States of America.